Acquired factor inhibitors are rare. We report a case of an elderly male who presented with a bleeding diathesis associated with an elevated prothrombin time and an activated partial thromboplastin time. Work-up revealed undetectable factor V activity and a factor V inhibitor level of >50 Bethesda units. The inhibitor may have been triggered by antibiotics. With a multimodality approach using steroids, platelet transfusions, intravenous immunoglobulin, factor VIII inhibitor bypass activity agent and cyclophosphamide, we successfully eliminated the inhibitor and controlled the bleeding.

Keywords:
Hemostasis, Acquired factor V inhibitor, Factor VIII inhibitor bypass activity agent
1.
Bouchard BA, Williams JL, Meisler NT, Long MW, Tracy PB: Endocytosis of plasma-derived factor V by megakaryocytes occurs via a clathrin-dependent, specific membrane binding event. J Thromb Haemost 2005;3:541–551.
2.
Morris CJ, Curry N: Aquired factor V inhibitor in a critically ill patient. Anaesthesia 2009;64:1014–1017.
3.
Wiwanitkit V: Spectrum of bleeding in acquired factor V inhibitor: a summary of 33 cases. Clin Appl Thromb Hemost 2006;12:485–488.
4.
Pei J, Li Q, Kennedy RT: Rapid and label-free screening of enzyme inhibitors using segmented flow electrospray ionization mass spectrometry. J Am Soc Mass Spectrom 2010;21:1107–1113.
5.
Tessier-Marteau A, Croquefer S, Meziani F, Cau S, Asfar P, Macchi L: Acquired factor V inhibitor in a context of sepsis and disseminated intravascular coagulation. Am J Hematol 2010;85:145–146.
6.
Favaloro EJ, Posen J, Ramakrishna R, Soltani S, McRae S, Just S, Aboud M, Low J, Gemmell R, Kershaw G, Coleman R, Dean M: Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation. Blood Coagul Fibrinolysis 2004;15:637–647.
7.
Ang AL, Kuperan P, Ng CH, Ng HJ: Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost 2009;101:852–859.
8.
Smith JD, Sindhi R, Rogers R, Lazarchick J: Factor V inhibitor in a liver transplant patient associated with porcine xenoperfusion. Ann Clin Lab Sci 1998;28:280–282.
9.
Lian EC, Tzakis AG, Andrews D: Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis. Am J Hematol 2004;77:363–365.
10.
Gordon B, Haire W, Duggan M, Langnas A, Shaw B Jr: Factor V inhibitor developing after liver transplantation in a 3-year-old child. Pediatrics 1991;88:156–159.
11.
Turecek PL, Váradi K, Gritsch H, Schwarz HP: FEIBA: mode of action. Hemophilia 2004;10:3–9.
12.
Monroe DM, Hoffman M, Oliver JA, Roberts HR: Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997;99:542–547.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.